STG Retatrutide: What It Is and What the Research Shows

STG retatrutide is a research-grade listing of the drug retatrutide sold by a third-party supplier using the name STG, not an FDA-approved medicine and not a pharmacy product. Retatrutide itself is an investigational triple receptor agonist developed by Eli Lilly that has not been approved for human use anywhere. Evaluating STG retatrutide means evaluating a vendor's purity testing, documentation, and shipping standards rather than a finished pharmaceutical.

What "STG Retatrutide" Really Means

STG is a supplier label, not a manufacturer. Eli Lilly develops and patents retatrutide, and no third-party vendor produces the brand-name compound. Research chemical sellers list it as a lyophilized powder labeled "for research use only."

• Vendor listings: STG-type listings usually state a purity percentage and offer a certificate of analysis (COA).
• Legal status: Research-grade retatrutide is not an approved drug and cannot legally be sold as a treatment for obesity or diabetes.
• What you're buying: A powder intended for laboratory work, not a sterile injectable medication with dosing instructions.

STG does not manufacture retatrutide, and no research supplier has published human clinical data on its own product.

Retatrutide Basics: Mechanism and Trial Status

Retatrutide is a single peptide that activates three hormone receptors at once: GIP, GLP-1, and glucagon. GIP and GLP-1 activity reduces appetite and slows stomach emptying, while glucagon receptor activity is thought to raise energy expenditure.

• It is given as a once-weekly subcutaneous injection in clinical trials.
• It has been studied in adults with obesity and in adults with type 2 diabetes.
• Eli Lilly has not announced a retatrutide brand name because the drug is still investigational.
• Phase 3 development continues under the TRIUMPH program.

Retatrutide is not FDA-approved, and no regulatory agency has cleared it for human use as of this writing.

What the Trial Data Show So Far

A phase 2 trial published in the New England Journal of Medicine in 2023 followed 338 adults with obesity for 48 weeks. Participants received weekly placebo or retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg.

These are trial averages, not guarantees for any individual. The 12 mg group was also the first in which every participant lost at least 5% of body weight.

Anyone searching how long does retatrutide take to work should know that weight loss in the trial was gradual: measurable changes generally appeared within the first 4 to 8 weeks and continued accumulating through week 48.

In trials, the retatrutide dosage was escalated slowly over several weeks to limit gastrointestinal side effects, a pattern used with other incretin-based drugs as well.

How Retatrutide Compares With Other Options

Retatrutide sits in a crowded field of incretin and amylin-based therapies. Some are approved for weight management and some remain investigational.

Readers searching survodutide vs retatrutide are comparing two investigational approaches that both rely on glucagon receptor activity, but only retatrutide adds GIP signaling. The popular comparison cagrilintide vs retatrutide vs tirzepatide spans three different mechanisms, which makes head-to-head conclusions premature until more phase 3 data are published.

Purity, Documentation, and Storage Checks

Research peptide quality varies widely between suppliers. If you are evaluating any STG retatrutide listing, the paperwork matters more than the marketing copy.

1. Match the batch number on the vial to the batch number printed on the certificate of analysis.
2. Look for third-party HPLC purity of 98% or higher.
3. Confirm that mass spectrometry data are included, not just a purity percentage.
4. Check that the supplier ships with cold packs and provides clear storage instructions.
5. Verify the vendor's return, reship, and dispute policies before ordering.

A certificate of analysis from an in-house lab carries far less weight than one issued by an independent, accredited testing facility.

Safety and Legal Considerations

Retatrutide has not been approved by the FDA for any use, and research-grade peptides are not produced under pharmaceutical sterile standards. The FDA has repeatedly warned that unapproved peptides sold online can be mislabeled, contaminated, or dosed incorrectly.

In clinical trials, the most common side effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation. Heart rate increases, injection-site reactions, and gallbladder problems were also reported. Anyone considering a GLP-1-related medication should talk with a licensed healthcare professional rather than self-experimenting with a research chemical.

Buying research peptides is legal in many US states for laboratory use, but selling them as drugs for human consumption is not. That distinction is the key to understanding what STG retatrutide is and what it is not.